XBiotech - Novel Antibody Bermekimab - Ownership and Business Overview

Life ScienceCompany

XBiotech - Novel Antibody Bermekimab Ownership

Who owns XBiotech - Novel Antibody Bermekimab?

XBiotech - Novel Antibody Bermekimab is owned by Janssen Pharmaceuticals. It was acquired on December 7, 2019.

XBiotech - Novel Antibody Bermekimab Business Overview

Where is XBiotech - Novel Antibody Bermekimab headquartered?

XBiotech - Novel Antibody Bermekimab is headquartered in Austin, Texas.

What sector is XBiotech - Novel Antibody Bermekimab in?

XBiotech - Novel Antibody Bermekimab is a life science company.

Life Science M&A Summary in 2019

Out of 60 sectors in the Mergr database, life science ranked 9 in number of deals in 2019. The largest life science acquisition in 2019 was Celgene - which was acquired by Bristol-Myers Squibb for $74.0B.

Join Mergr to view all 251 acquisitions of life science companies in 2019, including 44 acquisitions by private equity firms, and 207 by strategics.

XBiotech, Inc. - Novel Antibody Bermekimab

Austin, Texas
United States,

XBiotech, Inc.'s Novel Antibody Bermekimab provides disease-causing inflammation in a wide range of medical conditions.


 Subscribe to unlock this and 208,107
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 201K M&A Transactions
  • 203K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.